دورية أكاديمية
Four years of real-world sexual function outcomes after Rezum therapy in men with and without baseline erectile dysfunction.
| العنوان: | Four years of real-world sexual function outcomes after Rezum therapy in men with and without baseline erectile dysfunction. |
|---|---|
| المؤلفون: | Hawks-Ladds N; Albert Einstein College of Medicine, Bronx, NY 10461, United States., Cook R; Albert Einstein College of Medicine, Bronx, NY 10461, United States., Babar M; Albert Einstein College of Medicine, Bronx, NY 10461, United States., Zhu M; Albert Einstein College of Medicine, Bronx, NY 10461, United States., Schulz A; Albert Einstein College of Medicine, Bronx, NY 10461, United States., Loloi J; Department of Urology, Montefiore Medical Center, Bronx, NY 10467, United States., Masoud Z; Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, United States., Singh J; DSS Urology, Queens Village, NY 11427, United States., Jamil H; School of Public Health, St. Luke International University, Tokyo 104-8560, Japan., Sayed R; Albert Einstein College of Medicine, Bronx, NY 10461, United States., Ines M; DSS Urology, Queens Village, NY 11427, United States., Ciatto M; DSS Urology, Queens Village, NY 11427, United States. |
| المصدر: | The journal of sexual medicine [J Sex Med] 2024 Sep 03; Vol. 21 (9), pp. 777-786. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: Netherlands NLM ID: 101230693 Publication Model: Print Cited Medium: Internet ISSN: 1743-6109 (Electronic) Linking ISSN: 17436095 NLM ISO Abbreviation: J Sex Med Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : [Oxford] : Oxford University Press Original Publication: Malden, MA : Blackwell Pub. |
| مواضيع طبية MeSH: | Erectile Dysfunction*/drug therapy , Erectile Dysfunction*/etiology , Prostatic Hyperplasia*/complications, Humans ; Male ; Middle Aged ; Aged ; Surveys and Questionnaires ; Treatment Outcome ; Lower Urinary Tract Symptoms/drug therapy ; Lower Urinary Tract Symptoms/etiology ; Orgasm ; Patient Satisfaction/statistics & numerical data |
| مستخلص: | Background: Rezum alleviates lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) while preserving sexual function, but long-term sexual function outcomes are lacking in patients with baseline erectile dysfunction (ED). Aim: The study sought to analyze 4 years of real-world sexual function outcomes of Rezum using the International Index of Erectile Function (IIEF) questionnaire, stratified by baseline ED status. Methods: Participants included multiethnic Rezum-treated patients from a single outpatient office. IIEF domains and BPH medication usage were compared at baseline and 6, 12, and 48 months using t tests, Mann-Whitney U tests, chi-square tests, and Wilcoxon signed rank tests. Outcomes: Primary outcomes over 4 years included the IIEF functional domains (erectile function [EF], orgasmic function [OF], sexual desire [SD], intercourse satisfaction [IS], overall satisfaction [OS]) and BPH medication usage. Results: A total of 91 patients were included: 40 (44%) in the ED cohort and 51 (56%) in the no ED cohort. History of diabetes was more prevalent in the ED cohort (35% vs 15.7%; P = .048). Baseline scores in the EF, OF, IS, and OS domains were lower in the ED cohort. Compared with baseline, there were no significant changes in any IIEF domains in either cohort at 6 months. At 12 months, the ED cohort had significant percent decreases in OF (-25%; P = .02), SD (-22.2%; P = .04), and OS (-33.3%; P = .004); the no ED cohort had a significant percent increase in EF (5%; P = .04). At 48 months, the no ED cohort had no significant changes in any IIEF domains, while the ED cohort had significant percent increases in EF (30%; P = .01), SD (22.5%; P = .02), IS (20%; P = .01), and OS (58.3%; P = .008). Both cohorts significantly discontinued BPH medications at all follow-ups. At 48 months, there were no cases of de novo ED in the no ED cohort. Clinical Implications: As modern BPH therapies continue to demonstrate efficacy in alleviating lower urinary tract symptoms, the preservation or improvement of sexual function emerges as an increasingly important consideration for patients, with our study suggesting Rezum as a compelling option. Strengths and Limitations: Our study has the strength of long-term Rezum outcomes in an ethnically diverse patient population, stratified by the presence of baseline ED, but is limited by retrospective design, single-center nature, and small sample sizes at long-term follow-ups. Conclusion: Rezum preserved long-term sexual function in patients without baseline ED and improved sexual function in those with baseline ED; however, individuals with ED may experience temporary decreases in sexual function at 12 months. (© The Author(s) 2024. Published by Oxford University Press on behalf of The International Society of Sexual Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| فهرسة مساهمة: | Keywords: benign prostatic hyperplasia; erectile dysfunction; lower urinary tract symptoms; minimally invasive surgical procedures; physiological; prostate; prostatic diseases; sexual dysfunction |
| تواريخ الأحداث: | Date Created: 20240731 Date Completed: 20240904 Latest Revision: 20240904 |
| رمز التحديث: | 20240904 |
| DOI: | 10.1093/jsxmed/qdae087 |
| PMID: | 39084676 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1743-6109 |
|---|---|
| DOI: | 10.1093/jsxmed/qdae087 |